DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
Movement Disorders Clinical Practice2021Vol. 8(7), pp. 1061–1074
Citations Over TimeTop 10% of 2021 papers
David G. Standaert, Jason Aldred, Marieta Anca‐Herschkovitsch, Paul Bourgeois, Esther Cubo, Thomas L. Davis, Robert Iansek, Norbert Kovács, Francesco E. Pontieri, Mustafa Siddiqui, Mihaela Simu, Lars Bergmann, Pavnit Kukreja, Weining Robieson, К. Ray Chaudhuri
Abstract
These 12-month outcome data show sustained, long-term improvements and support the real-world effectiveness of LCIG in patients with advanced PD. Safety was consistent with previous studies.
Related Papers
- Clinical pharmacology of levodopa-induced dyskinesia.(2000)
- → Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease(2013)9 cited
- → Risk factors for levodopa-induced dyskinesia in Parkinson’s disease patients(2016)1 cited
- → Levodopa-responsive retrocollis on the background of choreic dyskinesia(2019)1 cited